An interventional study of Visual Array and Narrative Visual Array in Decision Aid, sponsored by Stephanie B. Seminara, MD. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Stephanie B. Seminara, MD · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States — 21 open to participants now, 33 under way, 2 of them phase 3. Colorectal Neoplasms, Hereditary Nonpolyposis · United States.
Among the 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States, this one is the 7th largest by enrollment of the 43 interventional ones that give a count, is one of 5 that started in 2025, is one of 28 with no phase, and was the 64th registered.
147 studies on the registry are indexed under Colorectal Neoplasms, Hereditary Nonpolyposis; 61 are open to participants now.
Browse Colorectal Neoplasms, Hereditary Nonpolyposis studies →21 of the 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States are open now. Recruiting first, the newest first:
Vividion Therapeutics, Inc. · Sites in United States, Argentina, Belgium and 19 more countries
Ages 18+
Jessica D. St. Laurent, MD · Sites in United States
Ages 18+ · Women only · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Healthy volunteers
University of Chicago · Sites in United States
Ages 20–80
University of Colorado, Denver · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Colorectal Neoplasms, Hereditary Nonpolyposis studies recruiting now, 32 (74%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 2
First in 1994; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,045 is above the median of 200 across 77 interventional studies indexed under Colorectal Neoplasms, Hereditary Nonpolyposis.
Median enrollment 162 across the 43 interventional studies, 300 across the 29 observational. Of the 32 that completed or were terminated, 7 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 72 have an industry lead sponsor. The 10 most frequent:
Stephanie B. Seminara, MD is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Stephanie B. Seminara, MD has 1 study filed under Colorectal Neoplasms, Hereditary Nonpolyposis — fewer than ten, so there is no comparison to draw.
8 of the studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00582296Memorial Sloan Kettering Cancer CenterMulti-Organ Screening Recommendations in Patients With Lynch Syndrome | 2026-12 |
| NCT02371135Memorial Sloan Kettering Cancer CenterMetagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes | 2027-02 |
| NCT07220239Jessica D. St. Laurent, MDMenstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome | 2027-03 |
| NCT05692596H. Lee Moffitt Cancer Center and Research InstituteThe Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics | 2027-07 |
| NCT05419011National Cancer Institute (NCI)Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome | 2027-07-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to understand how people understand risk from genetic testing. The investigators want to understand what visual aid best helps people accurately assess risk. The investigators also want to understand how people relate risk to their health. The main questions the study aims to answer are:
Participants will:
This study aims to determine what visual aid helps people most accurately interpret risk from genetic test results. The study also examines how people perceive risk using the Tripartite Risk Model. Last, the study examines factors that are associated with intention to share genetic test results with family members.
Participants will provide brief sociodemographic information, complete brief health literacy and numeracy assessments, and questions about how they perceive risk. Participants will be informed of a genetic testing scenario and will receive one of two visual aids. After reviewing the visual aid, participants will state the risk shown in the visual aid and will answer questions about their perceived risk and sharing results with family members (blood relatives).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Single, side-by-side visual array and non-directive decision frame
Behavioral: Visual Array · Behavioral: Choice
Single, side-by-side visual array and decision frame with subjective norms nudge
Behavioral: Visual Array · Behavioral: Enhanced Choice
Evolving narrative showing sequential visual arrays and non-directive decision frame
Behavioral: Narrative Visual Array · Behavioral: Choice
Evolving narrative showing sequential visual arrays and decision frame with subjective norms nudge
Behavioral: Narrative Visual Array · Behavioral: Enhanced Choice
Single side-by-side visual array
Evolving narrative with sequential visual arrays
Non-directive decision frame
Decision frame with subjective norms nudge
Perceived Overall Accuracy of General Population Risk for Colorectal Cancer Prior to Seeing Array
Differences between closest approximation to risk percentage depicted in the visual array that depicted risk with Lynch Syndrome (LS) minus risk without LS
Time frame: immediately after the intervention
Accuracy of Risk for Colorectal Cancer for Someone Without Lynch Syndrome (Without Gene Mutation) From the Array
Percent (%) estimated colorectal cancer risk for people like the general population. Closest approximation to risk percentage depicted in the visual array.
Time frame: immediately after the intervention
Accuracy of Risk for Colorectal Cancer for Someone With Lynch Syndrome From the Array
Percent (%) estimated colorectal cancer risk for people with Lynch Syndrome. Closest approximation to risk percentage depicted in the visual array showing the population of people with Lynch Syndrome
Time frame: immediately after the intervention
Risk Perceptions - Percent
Percent (%) estimated own lifetime risk for getting colorectal cancer. Perceptions of deliberative risk using 0-100 scale.
Time frame: baseline
Risk Perceptions - 7-point Likert-type Scale
Perceptions of affective and experiential risk using 7-point Likert-type scales 1. Strongly agree 2. Agree 3. Somewhat agree 4. Neither agree nor disagree 5. Somewhat disagree 6. Disagree 7. Strongly disagree Higher scores indicate greater affective and experiential perceived personal colorectal cancer risk.
Time frame: baseline
Communication Intent
Intent to communicate risk to blood relatives using 7-point Likert-type scale 1. Extremely unlikely 2. Unlikely 3. Somewhat unlikely 4. Neutral 5. Somewhat likely 6. Likely 7. Extremely likely Higher scores indicate greater expressed likelihood of communicating genetic risk to family members.
Time frame: immediately after the intervention
Online only recruitment and participation. All recruitment and participation occurred between 28 July and 18 August 2025.
| Milestone | Visual Array and Choice | Visual Array and Enhanced Choice | Narrative Visual Array and Choice | Narrative Visual Array and Enhanced Choice |
|---|---|---|---|---|
| Started | 276 | 257 | 256 | 252 |
| Completed | 266 | 249 | 244 | 242 |
| Not completed | 10 | 8 | 12 | 10 |
| Withdrew: Withdrawal by subject | 10 | 8 | 12 | 10 |
| Milestone | Visual Array and Choice | Visual Array and Enhanced Choice | Narrative Visual Array and Choice | Narrative Visual Array and Enhanced Choice |
|---|---|---|---|---|
| Started | 276 | 257 | 256 | 252 |
| Completed | 266 | 249 | 244 | 242 |
| Not completed | 10 | 8 | 12 | 10 |
| Withdrew: Withdrawal by subject | 10 | 8 | 12 | 10 |
Differences between closest approximation to risk percentage depicted in the visual array that depicted risk with Lynch Syndrome (LS) minus risk without LS
| Percent (%) | Visual Array | Narrative Visual Array |
|---|---|---|
| Perceived Overall Accuracy of General Population Risk for Colorectal Cancer Prior to Seeing Array | 13.65 ± 26.43 | 11.11 ± 25.16 |
Percent (%) estimated colorectal cancer risk for people like the general population. Closest approximation to risk percentage depicted in the visual array.
| Percent (%) | Visual Array | Narrative Visual Array |
|---|---|---|
| Accuracy of Risk for Colorectal Cancer for Someone Without Lynch Syndrome (Without Gene Mutation) From the Array | 46.17 ± 27.99 | 49.7 ± 27.92 |
Percent (%) estimated colorectal cancer risk for people with Lynch Syndrome. Closest approximation to risk percentage depicted in the visual array showing the population of people with Lynch Syndrome
| Percent (%) | Visual Array | Narrative Visual Array |
|---|---|---|
| Accuracy of Risk for Colorectal Cancer for Someone With Lynch Syndrome From the Array | 60.36 ± 15.86 | 60.91 ± 15.73 |
Percent (%) estimated own lifetime risk for getting colorectal cancer. Perceptions of deliberative risk using 0-100 scale.
| Percent (%) | Visual Array | Narrative Visual Array |
|---|---|---|
| Risk Perceptions - Percent | 3.38 ± 1.73 | 3.37 ± 1.76 |
Perceptions of affective and experiential risk using 7-point Likert-type scales 1. Strongly agree 2. Agree 3. Somewhat agree 4. Neither agree nor disagree 5. Somewhat disagree 6. Disagree 7. Strongly disagree Higher scores indicate greater affective and experiential perceived personal colorectal cancer risk.
| 7-point Likert-type scale score | Visual Array | Narrative Visual Array |
|---|---|---|
| Risk Perceptions - 7-point Likert-type Scale | 3.85 ± 0.57 | 3.86 ± 0.66 |
Intent to communicate risk to blood relatives using 7-point Likert-type scale 1. Extremely unlikely 2. Unlikely 3. Somewhat unlikely 4. Neutral 5. Somewhat likely 6. Likely 7. Extremely likely Higher scores indicate greater expressed likelihood of communicating genetic risk to family members.
| 7-point Likert-type scale score | Visual Array and Choice | Narrative Visual Array and Choice | Visual Array and Enhanced Choice | Narrative Visual Array and Enhanced Choice |
|---|---|---|---|---|
| Communication Intent | 5.14 ± 1.32 | 5 ± 1.46 | 5.14 ± 1.32 | 5 ± 1.46 |
Collected over Adverse events were collected from the time the participant began the study until completion of the survey - on average 12 minutes.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Visual Array and Choice | 0/276 (0%) | 0/276 (0%) | 0/276 (0%) |
| Visual Array and Enhanced Choice | 0/257 (0%) | 0/257 (0%) | 0/257 (0%) |
| Narrative Visual Array and Choice | 0/256 (0%) | 0/256 (0%) | 0/256 (0%) |
| Narrative Visual Array and Enhanced Choice | 0/252 (0%) | 0/252 (0%) | 0/252 (0%) |
| Age, Continuous(Year) | Visual Array | Narrative Visual Array | Total |
|---|---|---|---|
| Mean | 29.39 ± 2.7 | 41.99 ± 9.65 | 35.54 ± 9.43 |
| Sex/Gender, Customized(Participants) | Visual Array | Narrative Visual Array | Total |
|---|---|---|---|
| Female | 161 | 173 | 334 |
| Male | 367 | 328 | 695 |
| Unknown (Not reported) | 5 | 7 | 12 |
| Race (NIH/OMB)(Participants) | Visual Array | Narrative Visual Array | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 10 | 10 |
| Asian | 26 | 13 | 39 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 14 | 14 | 28 |
| White | 475 | 458 | 933 |
| More than one race | 0 | 4 | 4 |
| Unknown or Not Reported | 17 | 9 | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized data will be shared via the HarvardDataverse platform.
Time frame: Start date: within one month of the publication of study results. End date: one year after posting.
Access criteria: HarvardDataverse platform
Data sharing details ↗ · dataverse.harvard.edu
Ran from Jul 2025 to primary completion in Aug 2025, 0 months.
Results were first posted in Sep 2026, 1 year 1 month after primary completion.
Of 37 interventional studies with no phase under Colorectal Neoplasms, Hereditary Nonpolyposis, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 86. This study's 0 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Colorectal Neoplasms, Hereditary Nonpolyposis →
Stephanie B. Seminara, MD